- Molecular NameAtomoxetine
- SynonymTomoxetina [Spanish]; Tomoxetine; Tomoxetine [INN]; Tomoxetinum [Latin]
- Weight255.361
- Drugbank_IDDB00289
- ACS_NO83015-26-3
- Show 3D model
- LogP (experiment)4.656
- LogP (predicted, AB/LogP v2.0)3.7
- pka10.1
- LogD (pH=7, predicted)1.22
- Solubility (experiment)27.8 mg/mL
- LogS (predicted, ACD/Labs)(ph=7)-0.2
- LogSw (predicted, AB/LogsW2.0)0.05
- Sw (mg/ml) (predicted, ACD/Labs)0.33
- No.of HBond Donors1
- No.of HBond Acceptors2
- No.of Rotatable Bonds6
- TPSA21.26
- StatusFDA approved
- AdministrationN/A
- PharmacologyA drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD).
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- Bioavailability63.0
- Protein binding98.7
- Volume of distribution (VD)5.3 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmAtomoxetine is metabolized primarily through the CYP2D6 enzymatic pathway. The major oxidative metabolite formed, regardless of CYP2D6 status, is 4-hydroxyatomoxetine, which is glucuronidated. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs). 4-Hydroxyatomoxetine is primarily formed by CYP2D6, but in PMs, 4-hydroxyatomoxetine is formed at a slower rate by several other cytochrome P450 enzymes. N-Desmethylatomoxetine is formed by CYP2C19 and other cytochrome P450 enzymes, but has substantially less pharmacological activity compared with atomoxetine and circulates in plasma at lower concentrations (5% of atomoxetine concentration in EMs and 45% of atomoxetine concentration in PMs). Atomoxetine is excreted primarily as 4-hydroxyatomoxetine-O-glucuronide, mainly in the urine.
- Half life5.3 h
- ExcretionRenal (>80%) and fecal (<17%)
- Urinary Excretion1~2
- Clerance6.2 ml/min/kg
- ToxicityThe most commonly observed adverse reactions in patients treated with Strattera were: dyspepsia, nausea, vomiting, fatigue, appetite decreased, dizziness, and mood swings.
- LD50 (rat)N/A
- LD50 (mouse)N/A